Mindbio Therapeutics Corp.

As of March 31, 2026, Mindbio Therapeutics Corp. carries a market capitalization of 5.31M, placing it among publicly traded companies globally. Its enterprise value stands at 6.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Mindbio Therapeutics Corp. has 7.28M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Mindbio Therapeutics Corp. maintains a current ratio of 0.47, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -168.46, indicating conservative leverage, while an interest coverage ratio of -24.33 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2026. Return on assets (ROA) is negative at -1,146.26, reflecting losses generated across the asset base.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 0.10, while the 200-day moving average is 0.37.

Over the twelve months ended March 31, 2026, Mindbio Therapeutics Corp. generated - - in revenue and converted that into -4.25M in net income, yielding earnings per share of -1.26. EBITDA reached -3.84M, while operating income came in at -3.84M.

As of March 31, 2026, Mindbio Therapeutics Corp. holds 40,371.17 in cash and equivalents against 1.34M in total debt, resulting in a net debt position of 1.30M. Total book value stands at -755,550.44, with working capital of -793,746.51 providing operational flexibility.

Mindbio Therapeutics Corp. produced -979,867.91 in operating cash flow over the twelve months ended March 31, 2026.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -39.72: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -20.06, meaning Mindbio Therapeutics Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Mindbio Therapeutics Corp.'s most recent stock split took place on November 6, 2025 with a 400:1 split ratio.

As of March 31, 2026, Mindbio Therapeutics Corp. has an Altman Z-Score of -41.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.